Precigen doses first patients with UltraCAR-T cells

By The Science Advisory Board staff writers

November 17, 2020 -- Precigen said that the first patients in two phase I clinical trials have been treated with UltraCAR-T cells manufactured by its UltraPorator system.

In an ongoing phase I study conducted in collaboration with the University of Washington/Fred Hutchinson Cancer Research Center, PRGN-3005 UltraCAR-T cells were inserted in the intraperitoneal arm of patients as part of the study for advanced ovarian cancer patients, Precigen said.

Meanwhile, PRGN-3006 UltraCAR-T cells have also been used in dosing of patients with relapsed or refractory acute myeloid leukemia (AML) and higher risk myelodysplastic syndrome (MDS) as part of an ongoing phase I/IB study that's being conducted in collaboration with the Moffitt Cancer Center.

Precigen nabs FDA nod for manufacturing UltraCAR-T therapies
Precigen has been granted clearance by the U.S. Food and Drug Administration (FDA) for its UltraPorator system. The system also had a successful technology...
Precigen begins clinical trial for HPV-positive tumors
Precigen has dosed the first patients with Prgn-2009, an off-the-shelf investigational immunotherapy candidate, in a phase I/II clinical trial for the...
Microbe-based platform aims for sweet spot between biologics and gene therapy
A microbe-based therapeutics platform that has been in development for nearly 30 years is gaining traction for the treatment of inflammatory and autoimmune...
Precigen touts heart failure multigenic therapy results
Precigen is highlighting clinical results from a phase I trial conducted by its subsidiary Precigen Triple-Gene that show that its multigenic investigational...

Copyright © 2020

Microscopy and Microanalysis Meeting
July 31 - August 4
Portland, Oregon United States
Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter